Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: NVAX stock price vs SFNC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SFNC's multiple
Needs SFNC P/E.
Implied fair value · at NVAX's multiple
Needs EPS (TTM) is negative, NVAX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NVAX FY 2025 (ended Dec 31, 2025) · SFNC FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
NOVAVAX INC · implied price per share
Bear
$24.71
Base
$29.07
Bull
$33.44
SIMMONS FIRST NATIONAL CORP · implied price per share
Bear
$33.16
Base
$39.01
Bull
$44.86
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-0.00x
0.18x
Net debt / EBITDA
Leverage against operating earnings
-1.55x
-0.63x
Cash and equivalents
Liquid reserves on the balance sheet
$735.08M
$997.16M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
NVAX vs MRNA
BioNTech SE
NVAX vs BNTX
Emergent BioSolutions Inc.
NVAX vs EBS
ASTRAZENECA PLC
NVAX vs AZN
GSK plc
NVAX vs GSK
PINNACLE FINANCIAL PARTNERS INC
NVAX vs PNFP
UMB FINANCIAL CORP
NVAX vs UMBF
SYNOVUS FINANCIAL CORP
NVAX vs SNV
OLD NATIONAL BANCORP /IN/
NVAX vs ONB
$395.00K
$620.24M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
Live quote
